Attendee search 

Novartis Oncology profile

 A business unit within the Novartis Group, Novartis Oncology delivers a broad range of innovative therapies and practical solutions that help change the way patients live with cancer and blood disorders. Glivec® (imatinib) is an oral treatment for multiple rare diseases including forms of Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia (CML) and Kit (CD117)-positive gastrointestinal stromal tumors (GIST). Tasigna® (nilotinib) is approved for Ph+ CML adult patients resistant to or intolerant to at least one prior therapy. Afinitor® (everolimus) is indicated for patients with advanced renal cell carcinoma whose disease has progressed on or after treatment with vascular endothelial growth factor-targeted therapy. Zometa® (zoledronic acid) is indicated for the prevention of skeletal-related events in patients with advanced malignancies involving bone. Zometa also treats hypercalcemia of malignancy. Femara® (letrozole) is approved for adjuvant treatment of hormone receptor positive early breast cancer as well as for extended adjuvant treatment of hormone receptor positive early breast cancer after five years of initial tamoxifen therapy. It is also approved for several uses in certain postmenopausal women with advanced breast cancer. Sandostatin® LAR® (octreotide) helps control symptoms, such as severe diarrhea and flushing, associated with functional gastroenteropancreatic neuroendocrine tumors. It is also approved for the treatment of acromegaly. Exjade® (deferasirox) is approved to treat iron overload in a broad range of patients receiving ongoing blood transfusions. Novartis Oncology has a robust pipeline that utilizes recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies.

Partnering strategy

Novartis Oncology is seeking to license or acquire targeted therapeutic approaches to cancer treatment, with a particular interest in projects that have demonstrated Proof-of-Concept in human trials.

Jaleva Pharmaceuticals is a company focused on the improved delivery of active ingredients to the skin or mucosa.  We achieve this with our Patented Resin technology, and do so topically, and transmucosally.  The core of our Delivery is fast acting, and long lasting delivery of API's.

We currently have three products ready for license.  

1. A Surgical Prep product to compete with Chloraprep.

2. A Topical Pain Relief Spray, for two times a day use.

3. An NRT Trans-buccal product, quick acting, mimicking the craving reduction of a cigarette.

We have an array of other products in our development pipeline.  

Avanir Pharmaceuticals, Inc. is a biotechnology company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.  Our lead product, NUEDEXTA, is a dual sigma-1/NMDA receptor modulator and is the first and only FDA-approved treatment for pseudobulbar affect (PBA).  PBA is a condition affecting many patients with Alzheimer's / dementia, stroke, MS, Parkinson's, and other forms of neurological disease or injury and is characterized by uncontrolled episodes of crying or laughing.  

Avanir is commercializing NUEDEXTA in the United States through its specialty sales force calling primarily on neurology and psychiatry clinics as well as nursing homes.  Recent commercial milestones include over 10,000 Rx's during the month of August 2012 (up 9% relative to the prior month), which equates to a gross NUEDEXTA sales run-rate of over $65 million per year.

Avanir has a pending MAA for NUEDEXTA with the European regulatory authorities and is also conducting clinical trials in additional indications such as agitation in dementia, neuropathic pain in multiple sclerosis, and other areas where dual sigma-1/NMDA receptor targeted therapies can address unmet needs.    

Teikoku Pharma USA Inc., a wholly-owned subsidiary of Teikoku Seiyaku Inc. of Japan, is an international specialty pharmaceutical company that develops, and manufactures pharmaceutical products. Teikoku focuses its efforts in three therapeutic areas; Pain Management, CNS and Oncology.  Teikoku's main product is Lidoderm® (Lidocaine 5% Patch) for PHN, distributed by Endo Pharmaceuticals in the US, Grunenthal GmbH in Europe. Our core technology platforms include; passive and active transdermal delivery systems as well as injectables. We are currently actively seeking to in-license/acquire later stage product for the US, Europe and Japan.

Novartis Oncology profile

 A business unit within the Novartis Group, Novartis Oncology delivers a broad range of innovative therapies and practical solutions that help change the way patients live with cancer and blood disorders. Glivec® (imatinib) is an oral treatment for multiple rare diseases including forms of Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia (CML) and Kit (CD117)-positive gastrointestinal stromal tumors (GIST). Tasigna® (nilotinib) is approved for Ph+ CML adult patients resistant to or intolerant to at least one prior therapy. Afinitor® (everolimus) is indicated for patients with advanced renal cell carcinoma whose disease has progressed on or after treatment with vascular endothelial growth factor-targeted therapy. Zometa® (zoledronic acid) is indicated for the prevention of skeletal-related events in patients with advanced malignancies involving bone. Zometa also treats hypercalcemia of malignancy. Femara® (letrozole) is approved for adjuvant treatment of hormone receptor positive early breast cancer as well as for extended adjuvant treatment of hormone receptor positive early breast cancer after five years of initial tamoxifen therapy. It is also approved for several uses in certain postmenopausal women with advanced breast cancer. Sandostatin® LAR® (octreotide) helps control symptoms, such as severe diarrhea and flushing, associated with functional gastroenteropancreatic neuroendocrine tumors. It is also approved for the treatment of acromegaly. Exjade® (deferasirox) is approved to treat iron overload in a broad range of patients receiving ongoing blood transfusions. Novartis Oncology has a robust pipeline that utilizes recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies.

Partnering strategy

Novartis Oncology is seeking to license or acquire targeted therapeutic approaches to cancer treatment, with a particular interest in projects that have demonstrated Proof-of-Concept in human trials.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting with a current focus on already marketed or near to market hospital products.

Cadence has a highly experienced commercial group of 140+ hospital sales specialists, 14 MSLs and marketing team which are focused entirely on promotion to the hospital in the United States.  Our sales force is currently promoting OFIRMEV™ (acetaminophen injection), which is indicated for the treatment of acute pain and fever and we are now looking to expand our product offering.